Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Kalakonda · SciRah

Researcher profile · Semantic Scholar

N. Kalakonda

Share profile

N. Kalakonda — researcher profile on SciRah

h-index: 24
Works: 112
Citations: 2,560

Most-cited papers

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
G. Salles, J. Duell, E. González Barca, O. Tournilhac +13 more
2020The Lancet Oncology451 citations Open access
Semantic Scholar
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
N. Kalakonda, M. Maerevoet, F. Cavallo, G. Follows +33 more
2020The Lancet Haematology282 citations Open access
Semantic Scholar
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
J. Duell, K. Maddocks, E. González-Barca, W. Jurczak +17 more
2021Haematologica128 citations Open access
Semantic Scholar
CLL Exosomes Modulate the Transcriptome and Behaviour of Recipient Stromal Cells and Are Selectively Enriched in miR-202-3p
M. Farahani, C. Rubbi, Luning Liu, J. Slupsky +1 more
2015PLoS ONE81 citations Open access
Semantic Scholar
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial
R. Anderson, Rachel Remedios, A. Kirkwood, P. Patrick +10 more
2018The Lancet Oncology70 citations Open access
Semantic Scholar
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial
M. Gleeson, C. Peckitt, M. Ye, L. Edwards +24 more
2018The Lancet Haematology64 citations Open access
Semantic Scholar
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
J. Duell, P. Abrisqueta, M. André, G. Gaidano +13 more
2023Haematologica56 citations Open access
Semantic Scholar
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma
D. Austin, Rebecca H. Maier, Nasima Akhter, Mohammad Sayari +29 more
2024JACC CardioOncology42 citations Open access
Semantic Scholar
Identification of a novel BCL2‐specific inhibitor that binds predominantly to the BH1 domain
Divyaanka Iyer, Supriya V. Vartak, Archita Mishra, Gunaseelan Goldsmith +11 more
2016The FEBS Journal35 citations
Semantic Scholar
Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy.
Andrew D. Duckworth, M. Glenn, J. Slupsky, G. Packham +1 more
2014Blood34 citations Open access
Semantic Scholar
Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model
D. Pople, E. Monk, S. Evans, S. Foulkes +317 more
2022British medical journal32 citations Open access
Semantic Scholar
Multiplexed profiling of RNA and protein expression signatures in individual cells using flow or mass cytometry
Andrew D. Duckworth, P. Gherardini, Martina Sykorova, F. Yasin +3 more
2019Nature Protocols32 citations Open access
Semantic Scholar
The Management of Newly-Diagnosed Large B-cell Lymphoma: A British Society for Haematology Guideline
Christopher P. Fox, S. Chaganti, G. McIlroy, Sally F. Barrington +8 more
2024British Journal of Haematology29 citations Open access
Semantic Scholar
Loss of MIR15A and MIR16‐1 at 13q14 is associated with increased TP53 mRNA, de‐repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia
Ke Lin, M. Farahani, Yi Yang, G. G. Johnson +5 more
2014British Journal of Haematology29 citations
Semantic Scholar
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort
T. Bhogal, U. Khan, Rebecca Lee, A. Stockdale +19 more
2021Leukemia and Lymphoma27 citations Open access
Semantic Scholar
Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England
L. Hounsome, T. Eyre, R. Ireland, A. Hodson +8 more
2021British Journal of Cancer27 citations Open access
Semantic Scholar
Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind
G. Salles, J. Duell, E. González-Barca, W. Jurczak +12 more
2018Blood21 citations Open access
Semantic Scholar
Perspectives of patients with haematological cancer on how clinicians meet their information needs: “Managing” information versus “giving” it
K. Atherton, B. Young, N. Kalakonda, P. Salmon
2018Psycho-Oncology18 citations
Semantic Scholar
Deletion of 17p in cancers: Guilt by (p53) association
F. van Kampen, Abigail Clark, J. Soul, Aditi Kanhere +4 more
2025Oncogene17 citations
Semantic Scholar
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
G. Nowakowski, W. Willenbacher, R. Greil, T. Larsen +16 more
2021International journal of hematology16 citations
Semantic Scholar
Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome
K. Till, J. C. Allen, F. Talab, Ke Lin +8 more
2017Scientific Reports16 citations Open access
Semantic Scholar
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
M. Maerevoet, J. Zijlstra, G. Follows, R. Casasnovas +30 more
2021Journal of Hematology & Oncology15 citations Open access
Semantic Scholar
NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA
Andrew R. Pettitt, S. Barrington, N. Kalakonda, U. Khan +16 more
2019Hematological Oncology14 citations
Semantic Scholar
SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL
G. Nowakowski, W. Willenbacher, R. Greil, T. S. Larsen +15 more
2019Hematological Oncology12 citations Open access
Semantic Scholar
CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide
Jemma Blocksidge, M. Glenn, A. Gandhi, A. Klippel +3 more
201411 citations Open access
Semantic Scholar
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
J. Shah, S. Shacham, M. Kauffman, P. Daniele +32 more
2021Future Oncology10 citations Open access
Semantic Scholar
Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.
G. Nowakowski, W. Willenbacher, R. Greil, T. Larsen +15 more
2019Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Management of relapsed or refractory large B‐cell lymphoma: A British Society for Haematology Guideline
S. Chaganti, Christopher P. Fox, B. Maybury, Cathy Burton +8 more
2025British Journal of Haematology8 citations Open access
Semantic Scholar
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
R. Casasnovas, G. Follows, J. Zijlstra, J. Vermaat +29 more
2021Clinical Lymphoma, Myeloma & Leukemia8 citations Open access
Semantic Scholar
Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis.
K. Maddocks, J. Duell, E. González Barca, W. Jurczak +12 more
2019Journal of Clinical Oncology8 citations
Semantic Scholar
COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis
Y. Lim, U. Khan, Indrani Karpha, Andrew Ross +5 more
2022eJHaem6 citations Open access
Semantic Scholar
A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)
N. Kalakonda, F. Cavallo, G. Follows, A. Goy +27 more
2019Hematological Oncology6 citations
Semantic Scholar
Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study
M. Maerevoet, J. Vermaat, M. Canales, R. Casasnovas +27 more
2018Blood6 citations Open access
Semantic Scholar
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
Michaela Schuster, J. Zijlstra, R. Casasnovas, J. Vermaat +30 more
2021Clinical Lymphoma, Myeloma & Leukemia5 citations Open access
Semantic Scholar
PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND)
G. Salles, J. Duell, E. G. Barca, W. Jurczak +12 more
2019Hematological Oncology5 citations
Semantic Scholar
Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells
Ola Al-Sanabra, Andrew D. Duckworth, M. Glenn, Benjamin R. B. Brown +6 more
2017Scientific Reports5 citations Open access
Semantic Scholar
L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)—A single-arm phase II study.
K. Maddocks, E. G. Barca, W. Jurczak, A. Liberati +10 more
20175 citations Open access
Semantic Scholar
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T‐cell depletion and deletion of chromosome 17p
A. Arumainathan, N. Kalakonda, Andrew R. Pettitt
2011European Journal of Haematology5 citations
Semantic Scholar
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
J. Zijlstra, G. Follows, R. Casasnovas, J. Vermaat +26 more
2022Cancers4 citations Open access
Semantic Scholar
PKCβ Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling
Jodie Hay, Anuradha Tarafdar, Ailsa Holroyd, H. Moka +12 more
2022bioRxiv4 citations Open access
Semantic Scholar
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
A. Pettitt, R. Jackson, S. Cicconi, F. Polydoros +22 more
2020Haematologica4 citations Open access
Semantic Scholar
Ongoing Trials
A. Pettitt, S. Barrington, N. Kalakonda, U. Khan +3 more
20154 citations Open access
Semantic Scholar
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
J. Duell, P. Abrisqueta, M. André, M. Augustin +13 more
2023Hematological Oncology3 citations Open access
Semantic Scholar
Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells
Adam J. Linley, Laura I. Karydis, A. Mondru, A. D'Avola +13 more
2021Clinical Cancer Research3 citations Open access
Semantic Scholar
A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
N. Kalakonda, F. Cavallo, G. Follows, A. Goy +28 more
2019Clinical Lymphoma, Myeloma & Leukemia3 citations
Semantic Scholar
CHOP VERSUS GEM‐P IN THE FIRST‐LINE TREATMENT OF T‐CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO‐T TRIAL
M. Gleeson, C. Peckitt, M. Ye, L. Edwards +22 more
20173 citations Open access
Semantic Scholar
Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England
C. P. Fox, William Townsend, John Gribben, T. Menne +7 more
2024eJHaem2 citations Open access
Semantic Scholar
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
J. Duell, K. Maddocks, Eva Gonzalez-Barca, Wojciech Jurczak +17 more
2021Haematologica2 citations Open access
Semantic Scholar
Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study
M. Schuster, M. Canales, J. Westin, J. Zijlstra +34 more
20202 citations Open access
Semantic Scholar
Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial
J. Radford, J. Connors, A. Younes, A. Gallamini +16 more
2018Blood2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Maerevoet×10
Invite
M. Maerevoet — researcher profile on SciRah
F. Cavallo×10
Invite
F. Cavallo — researcher profile on SciRah
G. Follows×10
Invite
G. Follows — researcher profile on SciRah
J. Zijlstra×10
Invite
J. Zijlstra — researcher profile on SciRah

×10

Invite

S. Choquet — researcher profile on SciRah

Invite

R. Gurion — researcher profile on SciRah

C. Thieblemont×10

Invite

C. Thieblemont — researcher profile on SciRah

Invite

J. Duell — researcher profile on SciRah

Invite

K. Maddocks — researcher profile on SciRah

Invite

A. Goy — researcher profile on SciRah

Invite

J. Vermaat — researcher profile on SciRah

Invite

B. Hill — researcher profile on SciRah